Other psychoactive substance abuse with withdrawal delirium
ICD-10 F19.131 is a billable code used to indicate a diagnosis of other psychoactive substance abuse with withdrawal delirium.
F19.131 refers to a diagnosis of other psychoactive substance abuse characterized by the presence of withdrawal delirium. This condition arises when an individual who has been using psychoactive substances, such as hallucinogens, inhalants, or other non-specified drugs, experiences severe cognitive disturbances, altered consciousness, and perceptual disturbances upon cessation or reduction of substance use. Withdrawal delirium can manifest as confusion, agitation, hallucinations, and autonomic instability, which can pose significant risks to the patient’s health and safety. The diagnosis requires careful assessment of the patient's substance use history, clinical presentation, and the timing of withdrawal symptoms. Treatment typically involves supportive care, pharmacotherapy to manage symptoms, and rehabilitation programs to address the underlying substance use disorder. Accurate coding is essential for appropriate treatment planning and reimbursement.
Detailed psychiatric evaluation, including substance use history and mental status examination.
Patients presenting with acute confusion and agitation following substance cessation.
Consideration of co-occurring mental health disorders and their impact on treatment.
Comprehensive assessment of substance use patterns and withdrawal symptoms.
Patients in detoxification programs experiencing withdrawal delirium.
Integration of treatment plans with behavioral health interventions.
Used when assessing a patient with suspected withdrawal delirium.
Comprehensive mental health evaluation notes.
Psychiatric and addiction medicine specialists should document the assessment thoroughly.
Key symptoms include confusion, agitation, hallucinations, and autonomic instability, which can be life-threatening if not managed properly.
